Literature DB >> 35399506

Editorial: Extracellular Nucleotides in Lymphocyte Function.

Henrique Borges da Silva1, Maria Regina D'Imperio Lima2, Luiz Eduardo Baggio Savio3.   

Abstract

Entities:  

Keywords:  P2RX7; danger signal; ectonucleotidase; immune response; lymphocyte; nucleotides; solid tumor

Year:  2022        PMID: 35399506      PMCID: PMC8983866          DOI: 10.3389/fcell.2022.892303

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


× No keyword cloud information.
The optimal function of lymphocytes (e.g., T and B cells) requires the sensing of a plethora of signals, many of them coming from the extracellular environment. Many of these signals are actively produced and secreted by immune and non-immune cells, e.g., cytokines (Nolz and Richer, 2020). In addition, the passive release of intracellular metabolites plays an important role in regulating lymphocyte function and homeostasis. A prominent class of these metabolites comprises extracellular nucleotides, such as ATP. Release of extracellular ATP (eATP) is often understood as a “danger signal,” i.e., a factor that typifies a situation of threat to the host in face of a disturbance: infections, cancer, or autoimmunity (Di Virgilio et al., 2017). The signaling role of eATP is well-defined for innate immune cells as a crucial activator of the NLRP3 inflammasome (Mariathasan et al., 2006). In the last couple of decades, however, a growing body of work has highlighted the importance of signaling through eATP (and other extracellular nucleotides) for lymphocyte function. In this Special Issue, we present a mix of literature reviews and primary research shedding light on the latest advances in our understanding of this important subject. Release of eATP occurs at particularly high levels inside solid tumors, constituting a fundamental part of the tumor microenvironment (TME). Despite this prevalence, only recently the role of eATP signaling in regulating antitumor lymphocyte function has been done, especially focusing on T cells. The eATP receptor with the most well-defined immune function is the low-affinity P2RX7 ion channel (Di Virgilio et al., 2017). P2RX7 is expressed in antigen-experienced T cells, including those infiltrating solid tumors (Di Virgilio et al., 2017). Curiously, both the wild-type and mutant forms of P2RX7 are expressed at high levels by tumor cells themselves, with a seemingly pro-tumorigenic role. The concomitant expression of this receptor by tumor and T cells in the same TME makes it hard to predict and interpret how manipulation of this signaling pathway would influence the antitumoral T cell responses. The Perspective article by Grassi and Conti provides a comprehensive overview of the recent research and potential future directions on this subject. The association between P2RX7 and cancer is not limited to solid tumors, however. Perhaps linked to its expression in lymphocytes, P2RX7 is found to be expressed in certain hematologic tumor cells, such as leukemic cells. In fact, some of first connections between P2RX7 and oncogenesis were found on lymphocytic leukemia (Wiley and Dubyak, 1989). The Mini Review by De Marchi et al. shows the previous and recent discoveries on this subject and speculates about unanswered questions. P2RX7 is expressed in many distinct lymphocyte subsets, and recent research has unveiled how this receptor regulates these subsets (Di Virgilio et al., 2017). This is especially true for “helper” CD4+ T cells: it is now understood that P2RX7 promotes the cell death of regulatory T cells (Treg) and follicular helper T cells (Tfh) (Taylor et al., 2007; Proietti et al., 2014). In contrast, P2RX7 has a positive role for type 1 helper T cells (Th1) (Salles et al., 2017). Less is known about Th17 cells, a subset specialized in the production of the IL-17 cytokine and subsequent activation of antibacterial responses (Korn et al., 2009). The Article from Yang et al. describes how the expression of P2RX7 in CD4+ T cells (and in the antigen-presenting dendritic cells) can increase the Th17 differentiation potential of CD4+ T cells. Often after eATP release, ectonucleotidases present either in the extracellular environment or attached to cellular plasma membranes (e.g., CD39, CD73) can cleave eATP into its most common metabolites: eADP and the ultimate product, extracellular Adenosine. Opposite to eATP, Adenosine is typically understood as an immunomodulatory signal, being associated with T cell dysfunction in the context of solid tumors, which display high levels of Adenosine (Moesta et al., 2020). Less is understood about how ectonucleotidases and Adenosine influence lymphocyte function in the context of immune responses in solid, non-lymphoid organs. The Mini Review by Savio et al. addresses the previous and recent discoveries on how ectonucleotidases affect T cell responses in two specific organs, the gut and the liver, focusing on immune responses to autoimmune diseases in these organs. Expression of ectonucleotidases is a common feature of cytotoxic CD8+ T cells, such as CD39 (which cleaves eATP into eADP) and CD73, which leads to the production of Adenosine (Moesta et al., 2020). As exposed above, the presence of these receptors is often linked to dysfunction of CD8+ T cells. The Article from Briceño et al. offers additional evidence on this direction, showing that expression of CD73 by CD8+ T cells leads to decreased mitochondrial metabolism and associated lower ability to infiltrate and control melanoma tumors in mice, with simultaneous avoidance of acquisition of an exhaustion phenotype. It is less clear, however, how the immunomodulatory role of ectonucleotidases affects CD8+ T cell responses to antigen stimulation that ceases quickly (such as an acute infection). The Article from Rosemblatt et al. suggests an interesting scenario: while, during the antigen stimulation, CD73 expression leads to reduced CD8+ T cell viability, in the situation of homeostasis (which would occur, for example, after antigen is gone), CD73 favors CD8+ T cell survival. These results perhaps agree with the fact that some memory CD8+ T cells express CD73 (Fang et al., 2021). It will be necessary to understand how CD73 promotes such distinct outcomes in these two different scenarios in future studies. In summary, this Issue offers a comprehensive overview of how this sub-field stands nowadays. The discussions provided by these studies will be important, in our opinion, to shape future research aiming to better define how extracellular nucleotides affect lymphocyte function and homeostasis. In addition, they serve to highlight that eATP and Adenosine are much more than mere “danger-associated” signals as previously defined.
  10 in total

Review 1.  IL-17 and Th17 Cells.

Authors:  Thomas Korn; Estelle Bettelli; Mohamed Oukka; Vijay K Kuchroo
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

Review 2.  Control of memory CD8+ T cell longevity and effector functions by IL-15.

Authors:  Jeffrey C Nolz; Martin J Richer
Journal:  Mol Immunol       Date:  2019-12-06       Impact factor: 4.407

Review 3.  Targeting CD39 in cancer.

Authors:  Achim K Moesta; Xian-Yang Li; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2020-07-29       Impact factor: 53.106

4.  Extracellular adenosine triphosphate increases cation permeability of chronic lymphocytic leukemic lymphocytes.

Authors:  J S Wiley; G R Dubyak
Journal:  Blood       Date:  1989-04       Impact factor: 22.113

5.  Cryopyrin activates the inflammasome in response to toxins and ATP.

Authors:  Sanjeev Mariathasan; David S Weiss; Kim Newton; Jacqueline McBride; Karen O'Rourke; Meron Roose-Girma; Wyne P Lee; Yvette Weinrauch; Denise M Monack; Vishva M Dixit
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

6.  Regulatory T cells are resistant to apoptosis via TCR but not P2X7.

Authors:  Simon R J Taylor; Denis R Alexander; Joanne C Cooper; Christopher F Higgins; James I Elliott
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

7.  ATP-gated ionotropic P2X7 receptor controls follicular T helper cell numbers in Peyer's patches to promote host-microbiota mutualism.

Authors:  Michele Proietti; Vanessa Cornacchione; Tanja Rezzonico Jost; Andrea Romagnani; Caterina Elisa Faliti; Lisa Perruzza; Rosita Rigoni; Enrico Radaelli; Flavio Caprioli; Silvia Preziuso; Barbara Brannetti; Marcus Thelen; Kathy D McCoy; Emma Slack; Elisabetta Traggiai; Fabio Grassi
Journal:  Immunity       Date:  2014-11-13       Impact factor: 31.745

Review 8.  The P2X7 Receptor in Infection and Inflammation.

Authors:  Francesco Di Virgilio; Diego Dal Ben; Alba Clara Sarti; Anna Lisa Giuliani; Simonetta Falzoni
Journal:  Immunity       Date:  2017-07-18       Impact factor: 31.745

9.  The cell-surface 5'-nucleotidase CD73 defines a functional T memory cell subset that declines with age.

Authors:  Fengqin Fang; Wenqiang Cao; Weikang Zhu; Nora Lam; Lingjie Li; Sadhana Gaddam; Yong Wang; Chulwoo Kim; Simon Lambert; Huimin Zhang; Bin Hu; Donna L Farber; Cornelia M Weyand; Jörg J Goronzy
Journal:  Cell Rep       Date:  2021-11-09       Impact factor: 9.423

10.  P2X7 receptor drives Th1 cell differentiation and controls the follicular helper T cell population to protect against Plasmodium chabaudi malaria.

Authors:  Érika Machado de Salles; Maria Nogueira de Menezes; Renan Siqueira; Henrique Borges da Silva; Eduardo Pinheiro Amaral; Sheyla Inés Castillo-Méndez; Isabela Cunha; Alexandra Dos Anjos Cassado; Flávia Sarmento Vieira; David Nicholas Olivieri; Carlos Eduardo Tadokoro; José Maria Alvarez; Robson Coutinho-Silva; Maria Regina D'Império-Lima
Journal:  PLoS Pathog       Date:  2017-08-31       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.